23 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
- 1367.1 An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Multiple phase 1 Closed any line, RECIST 1.1
- AMC303-01 A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Multiple phase 1/1b Closed any line, RECIST 1.1
- ARASENS A randomized, double blind, placebo controlled Phase III study of ODM 201 versus placebo in addition to standard androgen deprivation therapy and docetaxel in patients with metastatic hormone sensitive prostate cancer prostate phase 3 Closed Metastatic
- BAY 88-8223 / 16996 A Phase 4 long-term follow-up study to define the safety profile of radium-223 dichloride Multiple phase 4 Closed Subject was previously enrolled in a selected company-sponsored feeder trial, and has received at least 1 dose of radium-223 dichloride or placebo in the feeder trial.
- CAPItello-281 A Phase III Double-Blind, Randomised, Placebo-Controlled Study Assessing the Efficacy and Safety of Capivasertib + Abiraterone Versus Placebo + Abiraterone as Treatment for Patients with De Novo Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Characterised by PTEN deficiency (CAPItello-281) prostate phase 3 Open
- CONTACT 02 A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with High-Risk, Metastatic Castration-Resistant Prostate Cancer prostate phase 3 Closed
- EORTC 1658 Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Lung Closed any line / Lung metastasis
-
ERA-223
A phase III randomized, double-blind, placebo-controlled trial of radium-223 dichloride in combination with abiraterone acetate and prednisone/prednisolone in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve subjects with bone predominant metastatic castration-resistant prostate cancer (CRPC)
prostate
phase
3
Closed
*Histologically confirmed adenocarcinoma of the prostate
*Prostate cancer progression documented by PSA according to the Prostate Cancer
Working Group 2 (PCWG2) criteria or radiological progression
according to RECIST, version 1.1
*Two or more bone meta - EVICTION A fist-in-human, two-part, open-label, clinical study to assess the safety, tolerability and activity of intravenous doses of ICT01 as monotherapy and in combination with an Immune Checkpoint Inhibitor, in patients with advanced-stage, relapsed/refractory cancer Multiple phase 1 Open Relasped/refractory patient
- Galahad A phase 2 efficacy and safety study of Niraparib in men with metastatic castration-resistant prostate cancer and DNA repair anomalies. prostate phase 2 Closed 2nd line/ RECIST 1.1/ Biopsy
- I7W-MC-JQBA A Phase 1 Study of LY3127804 as Monotherapy and in Combination with Ramucirumab in Patients with Advanced Solid Tumors Multiple phase 1 Closed RECIST 1.1, after standard trerapy
- IJB_2728 Improving emotion regulation for patients with metastatic cancer: A pilot study assessing the impact of a multi-component psychological group intervention Solid tumors Open Metastatic, any tumors
- Intervention destinée aux parents L'enfant face au cancer d'un parent: une étude randomisée évaluant l'efficacité d'une intervention psychologique destinée à soutenir la parentalité Solid tumors Open Be a parent or close relative of a child between the ages of 3 and 18 confronted with parental cancer, any tumors
- LPS14201 ? CARD A randomized, open label, multicenter study of Cabazitaxel versus an Androgen Receptor (AR)-targeted agent (abiraterone or enzalutamide) in mCRPC patients previously treated with Docetaxel and who rapidly failed a prior AR-targeted agent (CARD) prostate phase 3 Closed Metastatic castration resistant prostate cancer after progression to docetaxel and androgen-receptor targeted agent.